SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results Read more about SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox Read more about SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX® Read more about SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX® SIGA Announces Approximately $16 Million of International Procurement Orders Received in August and Early September for Oral TPOXX® (Tecovirimat) Read more about SIGA Announces Approximately $16 Million of International Procurement Orders Received in August and Early September for Oral TPOXX® (Tecovirimat) SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX® Read more about SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX® SIGA Reports Financial Results for Three and Six Months Ended June 30, 2022 Read more about SIGA Reports Financial Results for Three and Six Months Ended June 30, 2022 SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results Read more about SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results We have monkeypox treatments – but must act fast Read more about We have monkeypox treatments – but must act fast SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics Read more about SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat) Read more about SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat) Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to
SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results Read more about SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results
SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox Read more about SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox
SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX® Read more about SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX®
SIGA Announces Approximately $16 Million of International Procurement Orders Received in August and Early September for Oral TPOXX® (Tecovirimat) Read more about SIGA Announces Approximately $16 Million of International Procurement Orders Received in August and Early September for Oral TPOXX® (Tecovirimat)
SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX® Read more about SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX®
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2022 Read more about SIGA Reports Financial Results for Three and Six Months Ended June 30, 2022
SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results Read more about SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results
We have monkeypox treatments – but must act fast Read more about We have monkeypox treatments – but must act fast
SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics Read more about SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics
SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat) Read more about SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)